Q32 Bio Inc. (DB0)
FSX
Real-time Data
06:00 AM
Day's Range
13.5352 wk Range
1.37Overview - DB0 - Q32 Bio Inc.
Key Statistics
Valuation
Enterprise Value
258.48M
P/E (Trailing)
‪5.02‬
PEG Ratio
‪-0.11‬
Price / Sales (TTM)
‪7.49‬
Price / Book
‪3.51‬
EV / EBITDA
‪13.83‬
Profitability
Profit Margin
‪62.87%‬
Operating Margin
‪39.93%‬
Return on Assets
‪14.74%‬
Return on Equity
‪72.13%‬
Ownership
Shares Outstanding
29.76M
Float
14.47M
Held by Insiders
‪2.82%‬
Held by Institutions
‪76.26%‬
Price stats
Beta
‪-0.32‬
50-Day Avg
‪12.47‬
200-Day Avg
‪6.43‬
Dividends
Payout Ratio
‪0.00%‬
Peers - DB0 - Q32 Bio Inc.
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
- DB0FSXQ32 Bio Inc.174.31MMarket Cap+87.44%52-week change4.28P/E (Trailing)‪61.86%‬Profit Margin
- ANLFSXAnalog Devices, Inc.152.94BMarket Cap+29.62%52-week change44.47P/E (Trailing)‪29.78%‬Profit Margin
- 1AEFSXargenx SE56.27BMarket Cap+30.57%52-week change39.07P/E (Trailing)‪32.26%‬Profit Margin
- 1AEAFSXargenx SE American Depositary Receipt54.72BMarket Cap+33.14%52-week change39.13P/E (Trailing)‪32.26%‬Profit Margin
- 0QFFSXModerna, Inc.50.02BMarket Cap+81.89%52-week change25.27P/E (Trailing)‪-141.42%‬Profit Margin
- 42ZFSXRevolution Medicines Inc.37.93BMarket Cap+83.17%52-week change-30.35P/E (Trailing)‪0.00%‬Profit Margin
- 49BAFSXBeOne Medicines, Ltd. American Depositary Receipt35.29BMarket Cap+16.03%52-week change65.41P/E (Trailing)‪10.69%‬Profit Margin
Profile Summary - DB0 - Q32 Bio Inc.
About
Q32 Bio Inc. is a clinical-stage biotechnology company developing biologic therapeutics that target potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its primary focus is on bempikibart (ADX-914), a fully human anti-IL-7Rα antibody designed to…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
